Mon Sep 30 05:17:10 UTC 2024: ## Intellia Therapeutics Receives “Moderate Buy” Rating from Analysts

**[City, State] -** Intellia Therapeutics, Inc. (NASDAQ: NTLA), a genome editing company focused on developing curative therapies, has garnered a “Moderate Buy” consensus rating from fifteen brokerages covering the stock, according to MarketBeat.

The rating reflects a positive outlook on the company, with ten analysts issuing a “Buy” recommendation and one issuing a “Strong Buy” recommendation. Four analysts maintained a “Hold” rating. The average one-year price target for Intellia Therapeutics is $61.77, suggesting potential upside from its current trading price.

Recent research reports from various analysts have highlighted both potential and challenges for Intellia. Stifel Nicolaus decreased their target price to $64.00 but maintained a “Buy” rating, while Royal Bank of Canada restated an “Outperform” rating with a $54.00 target. Truist Financial reiterated a “Buy” rating with a $120.00 price objective, while Evercore ISI upgraded the stock to a “Strong-Buy” rating. Canaccord Genuity Group maintained a “Buy” rating with a $73.00 target price.

Despite missing analyst estimates in its recent earnings report, Intellia continues to attract investor interest. Several hedge funds have recently adjusted their positions in the company, with some increasing their holdings while others initiating new positions. Institutional investors currently own 88.77% of Intellia’s outstanding shares.

Intellia is currently developing several in vivo programs, including NTLA-2001 for transthyretin amyloidosis, NTLA-2002 for hereditary angioedema, and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

The company’s progress in developing these therapies, along with the strong interest from analysts and investors, suggests that Intellia Therapeutics remains a promising player in the genome editing space.

Read More